Details of the Drug

General Information of Drug (ID: DMRICNP)

Drug Name
Vandetanib
Synonyms
Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor)
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1]
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01EX04: Vandetanib
L01EX: Other protein kinase inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 475.4
Logarithm of the Partition Coefficient (xlogp) 4.9
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 19 days [3]
Metabolism
The drug is metabolized via plasma []
Vd
The volume of distribution (Vd) of drug is 7450 L []
Chemical Identifiers
Formula
C22H24BrFN4O2
IUPAC Name
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
Canonical SMILES
CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC
InChI
InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)
InChIKey
UHTHHESEBZOYNR-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3081361
ChEBI ID
CHEBI:49960
CAS Number
443913-73-3
UNII
YO460OQ37K
DrugBank ID
DB05294
TTD ID
D0G6QF
VARIDT ID
DR00618
INTEDE ID
DR1669
ACDINA ID
D00720
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [4]
Proto-oncogene c-Ret (RET) TT4DXQT RET_HUMAN Inhibitor [4]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Inhibitor [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [5]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [6]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [7]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Protein Interaction/Cellular Processes [8]
Angiopoietin-related protein 4 (ANGPTL4) OTQL5SPX ANGL4_HUMAN Gene/Protein Processing [9]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L) OTJKOMXE BNI3L_HUMAN Gene/Protein Processing [9]
Calbindin (CALB1) OTM7IXDG CALB1_HUMAN Gene/Protein Processing [9]
Collagen alpha-3(IV) chain (COL4A3) OT6SB8X5 CO4A3_HUMAN Gene/Protein Processing [9]
DNA mismatch repair protein Msh3 (MSH3) OTD3YPVL MSH3_HUMAN Gene/Protein Processing [9]
Dual specificity protein phosphatase 1 (DUSP1) OTN6BR75 DUS1_HUMAN Gene/Protein Processing [9]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Gene/Protein Processing [10]
Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) OTHBQVD5 4EBP1_HUMAN Post-Translational Modifications [11]
Gamma-enolase (ENO2) OTRODL0T ENOG_HUMAN Gene/Protein Processing [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor receptor 2 (KDR) DTT KDR 1.98E-01 0.11 0.2
Breast cancer resistance protein (ABCG2) DTP BCRP 9.45E-01 -5.34E-02 -9.01E-02
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 9.69E-01 1.16E-03 3.56E-03
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 8.15E-01 6.20E-03 5.61E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SK-N-SH CCLE 2.6071 5.3135 1.5014 9.1524
SK-N-DZ CCLE 2.9257 5.1586 1.8582 6.3741
IMR-32 CCLE 3.0294 4.9959 2.0264 5.2028
CHP-212 CCLE 3.1157 14.4649 -2.6363 25.9203
SK-N-FI CCLE 3.1473 9.0241 0.1098 15.0201
Kelly CCLE 3.3844 6.8584 1.381 7.8548
KP-N-SI9s CCLE 3.5208 7.2462 1.2938 8.0169
SiMa CCLE 3.6082 15.7389 -2.87 25.4335
SK-N-AS CCLE 4.0317 9.1302 0.7464 9.7874
SK-N-BE(2) CCLE 4.4652 12.0984 -0.3933 14.3696
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 CCLE 3.4188 7.5223 1.0777 9.3945
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U2OS CCLE 2.0541 6.1165 0.5971 15.5332
A-673 CCLE 2.4425 6.223 0.9032 12.8063
SK-ES-1 CCLE 2.9983 8.1239 0.4366 13.7586
MHH-ES-1 CCLE 3.1557 7.2386 1.009 10.3795
HOS CCLE 3.2879 7.2709 1.0995 9.5822
SJSA-1 CCLE 3.6066 8.6049 0.6856 11.0211
MG-63 CCLE 3.7196 6.4362 1.8384 4.7127
SaOS-2 CCLE 3.7839 9.0519 0.6 11.065
CAL-78 CCLE 3.955 5.7618 2.3104 1.9235
SW1353 CCLE 4.0192 7.186 1.6834 4.9597
TC-71 CCLE 5.6741 7.1707 2.5212 0.1143
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CAL-85-1 CCLE 0.3168 4.8315 -0.5729 27.0512
HDQ-P1 CCLE 0.9649 6.172 -0.4897 24.318
MDA-MB-468 CCLE 1.4289 9.4084 -1.5922 27.2005
HCC1806 CCLE 1.7532 4.7413 0.9542 14.6301
HCC1954 CCLE 1.9857 6.5912 0.302 17.2427
EFM-19 CCLE 2.2151 6.5704 0.5248 15.4309
BT-549 CCLE 2.524 4.7248 1.7147 8.2471
BT-20 CCLE 2.6576 5.3188 1.5442 8.7829
MDA-MB-157 CCLE 2.9182 8.1466 0.3582 14.3613
UACC-812 CCLE 2.9243 6.7058 1.0837 10.5559
ZR-75-1 CCLE 3.1216 5.7817 1.7091 6.6974
BT-474 CCLE 3.1264 6.3835 1.4124 8.2886
SK-BR-3 CCLE 3.1389 6.5264 1.3512 8.5881
MDA-MB-453 CCLE 3.1858 5.6605 1.8212 5.9395
Hs 739.T CCLE 3.2147 5.7091 1.82 5.8792
HCC1395 CCLE 3.2191 8.5477 0.4065 13.3614
HCC70 CCLE 3.2422 8.8689 0.2649 14.018
ZR-75-30 CCLE 3.2563 5.4271 1.9929 4.8516
HCC1569 CCLE 3.2806 7.5681 0.9454 10.4171
AU565 CCLE 3.4192 5.637 2.0124 4.3944
MDA-MB-175-VII CCLE 3.432 5.3765 2.1498 3.6371
HCC1187 CCLE 3.6799 11.8185 -0.8562 18.142
MCF-7 CCLE 3.6903 14.5858 -2.2281 23.257
Hs 578T CCLE 3.7727 6.5333 1.8285 4.6628
CAMA-1 CCLE 3.865 6.3968 1.9571 3.8263
MDA-MB-415 CCLE 4.0029 7.4763 1.5325 5.771
T-47D CCLE 4.2084 7.5208 1.6499 4.796
MDA-MB-436 CCLE 4.3071 7.1023 1.9088 3.3422
HMC-1-8 CCLE 4.8272 13.6585 -0.8937 15.7758
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
8-MG-BA CCLE 0.5428 6.1196 -0.8915 27.5444
42-MG-BA CCLE 1.7952 8.7508 -0.9322 23.5203
T98G CCLE 2.1234 7.5726 -0.0524 18.5827
1321N1 CCLE 2.57 6.3517 0.9535 12.1855
KNS-60 CCLE 3.0142 5.0233 2.0002 5.3824
KNS-81 CCLE 3.2017 9.1525 0.0902 14.9812
DK-MG CCLE 3.249 8.3012 0.5539 12.5359
LN-229 CCLE 3.2825 7.169 1.146 9.3469
Daoy CCLE 3.4631 6.451 1.6436 6.2732
GB-1 CCLE 3.504 6.0391 1.8773 4.9384
H4 CCLE 3.6936 10.0327 0.0437 14.0325
U-118MG CCLE 3.8093 11.7457 -0.718 17.2491
SW1088 CCLE 3.8313 6.8909 1.6962 5.2434
GaMG CCLE 3.9201 8.7592 0.8466 9.5065
SF126 CCLE 4.0829 7.1854 1.7264 4.6247
Hs 683 CCLE 4.1134 6.4552 2.0886 2.7589
ONS-76 CCLE 4.3742 7.8179 1.6174 4.6799
GI-1 CCLE 4.4217 8.2794 1.4303 5.5413
MOG-G-CCM CCLE 4.4637 7.82 1.6732 4.2568
CAS-1 CCLE 4.5104 11.5046 -0.0686 12.7904
M059J CCLE 4.6473 7.8984 1.7494 3.6075
KNS-42 CCLE 4.6704 11.6302 -0.0146 12.2145
GMS-10 CCLE 4.685 10.0802 0.7467 8.5066
U-87MG ATCC CCLE 4.9581 7.0821 2.2682 1.0287
SF295 CCLE 4.9989 6.2828 2.5855 0.1614
KALS-1 CCLE 5.2313 15.84 -1.6687 17.9794
DBTRG-05MG CCLE 5.2802 9.1871 1.5366 3.7322
YKG-1 CCLE 5.4775 12.7005 0.0267 10.5069
A-172 CCLE 7.0028 20.1726 -2.5227 17.659
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
AN3-CA CCLE 0.8751 4.8741 -0.0055 22.3999
HEC-151 CCLE 0.8895 5.9012 -0.4421 24.3687
MFE-296 CCLE 1.0193 6.3968 -0.539 24.3484
MFE-319 CCLE 1.086 5.2085 0.0673 21.3089
HEC-1-B CCLE 1.5482 6.1604 0.0916 19.647
RL95-2 CCLE 1.7523 5.5711 0.569 16.6076
JHUEM-2 CCLE 1.7706 3.728 1.4075 12.2751
KLE CCLE 1.8766 6.2894 0.3456 17.3545
MFE-280 CCLE 2.2195 4.9906 1.2976 11.3676
HEC-251 CCLE 2.5174 7.2519 0.4596 14.9112
HEC-6 CCLE 2.846 6.44 1.15 10.4017
HEC-265 CCLE 3.1375 4.7317 2.2459 3.7565
EFE-184 CCLE 3.1596 7.9341 0.6646 12.1816
ESS-1 CCLE 3.3609 6.6439 1.4694 7.4342
HEC-1-A CCLE 3.4457 7.3429 1.1879 8.748
TEN CCLE 3.8603 7.0288 1.6498 5.4308
EN CCLE 4 12.8667 -1.1267 18.5151
HEC-59 CCLE 4.3278 6.7821 2.0674 2.5505
Ishikawa (Heraklio) 02 ER- CCLE 1.9771 6.8744 0.1559 17.9981
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 71 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Ku812 CCLE -1.1959 0.8719 -1.2174 36.1253
KG-1 CCLE -0.4176 1.8496 -0.4902 29.6654
ALL-SIL CCLE -0.2729 1.996 -0.3562 28.4705
NCO2 CCLE -0.1728 1.6446 -0.2078 27.4006
EM-2 CCLE -0.0655 2.4059 -0.204 26.9356
BDCM CCLE 0.2109 4.7322 -0.6448 27.7698
Pfeiffer CCLE 0.341 2.6493 0.1859 23.5251
KCL-22 CCLE 0.6664 3.5238 0.2932 21.7502
MEG-01 CCLE 0.6699 2.5506 0.5642 20.4794
HuT 78 CCLE 0.8392 3.6537 0.4357 20.4194
BL-70 CCLE 1.0856 3.0001 0.9107 17.2298
SU-DHL-4 CCLE 1.324 3.9839 0.8324 16.7146
Ci-1 CCLE 1.3333 8.2955 -1.1389 25.8067
Mono-Mac-1 CCLE 1.3683 4.2332 0.7783 16.8257
Jurkat CCLE 1.4727 6.7131 -0.2442 21.496
MJ CCLE 1.6108 8.3102 -0.8862 23.8983
JVM-3 CCLE 1.6373 10.3048 -1.8421 27.4246
KMS-26 CCLE 1.751 6.5768 0.0877 19.0248
SU-DHL-6 CCLE 1.8726 3.5127 1.5996 10.9611
SK-MM-2 CCLE 1.8787 5.9237 0.5237 16.4441
AMO1 CCLE 2.215 3.1858 2.0862 7.335
697 CCLE 2.3116 6.3208 0.736 14.057
Mino CCLE 2.4272 3.7513 2.0821 6.6106
SU-DHL-10 CCLE 2.4564 3.4733 2.2338 5.7383
EB1 CCLE 2.4662 4.9835 1.5346 9.376
Granta-519 CCLE 2.5269 8.6696 -0.2381 18.3224
RPMI-8402 CCLE 2.5335 5.5204 1.3327 10.2634
P3HR-1 CCLE 2.6238 7.924 0.2179 15.8448
MEC-1 CCLE 2.7421 9.6488 -0.5416 19.1301
HH [Human lymphoma] CCLE 2.7788 4.6852 1.9666 6.1753
KE-97 CCLE 2.7945 6.4081 1.1218 10.6867
DoHH2 CCLE 2.8444 6.1422 1.2974 9.614
MOLT-16 CCLE 2.9663 8.2269 0.3584 14.2374
SU-DHL-8 CCLE 3.0143 4.4596 2.2821 3.8549
DEL CCLE 3.0279 5.6733 1.6865 7.0478
HT CCLE 3.1007 15.7407 -3.2866 27.784
EB2 CCLE 3.1416 5.0722 2.0794 4.6473
Toledo CCLE 3.1843 6.0384 1.6315 6.9682
KMS-11 CCLE 3.2009 7.1529 1.0885 9.8472
L-363 CCLE 3.2613 5.8195 1.8016 5.8715
Raji CCLE 3.2807 5.9138 1.7699 5.9985
CMK-86 CCLE 3.2852 6.2114 1.6253 6.7673
MC116 CCLE 3.2964 6.9365 1.273 8.6357
SUP-T1 CCLE 3.3848 6.4003 1.6089 6.6313
KHM-1B CCLE 3.4552 7.5407 1.097 9.2097
P12-Ichikawa CCLE 3.497 6.3123 1.7376 5.698
U-937 CCLE 3.5834 6.1458 1.8829 4.7467
KMS-12-BM CCLE 3.609 5.3814 2.2706 2.669
SIG-M5 CCLE 3.6146 8.1013 0.9417 9.671
KMS-34 CCLE 3.7559 5.3866 2.3624 1.9651
OCI-AML-2 CCLE 3.8263 7.2241 1.5307 6.1217
KMM-1 CCLE 3.8406 8.3721 0.9783 8.9911
HEL 92.1.7 CCLE 3.8448 6.6475 1.8232 4.5553
OPM-2 CCLE 3.9276 6.7328 1.8386 4.3242
Karpas-299 CCLE 4.1216 6.0388 2.2822 1.8295
OCI-AML-5 CCLE 4.1254 8.598 1.0745 7.9113
P31/FUJ CCLE 4.1814 6.1311 2.2749 1.786
Karpas-620 CCLE 4.1925 5.827 2.413 1.1717
SUP-M2 CCLE 4.1939 5.5776 2.5179 0.7568
BL-41 CCLE 4.4738 5.8276 2.5454 0.463
MOLP-8 CCLE 4.4816 6.7778 2.1562 1.9467
KO52 CCLE 4.4899 7.9688 1.6203 4.4768
Reh CCLE 4.5659 6.1569 2.4576 0.6771
L-428 CCLE 4.6609 13.4294 -0.9035 16.1601
HD-MY-Z CCLE 4.7816 8.4672 1.5699 4.2727
Karpas-422 CCLE 4.7959 6.3589 2.479 0.4706
LP-1 CCLE 5.0489 7.2682 2.2356 1.0719
F-36P CCLE 5.1822 17.3944 -2.4694 20.8189
Kasumi-2 CCLE 5.2336 13.5326 -0.541 13.4784
JM-1 CCLE 5.8375 7.2657 2.5453 0.0705
OCI-Ly10 CCLE 6.1802 8.5384 2.2287 0.4643
⏷ Show the Full List of 71 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
VMRC-RCW CCLE 0.683 1.7941 0.6727 19.9432
ACHN CCLE 0.8687 5.7487 -0.3945 24.2278
KMRC-2 CCLE 1.5378 9.3099 -1.4434 26.3184
Caki-2 CCLE 1.8144 10.4882 -1.7729 26.6557
769-P CCLE 1.8403 5.578 0.6514 15.9087
VMRC-RCZ CCLE 2.7242 5.3835 1.5713 8.4551
BFTC-909 CCLE 3.3835 6.2933 1.661 6.3544
KMRC-1 CCLE 3.6048 12.4334 -1.2227 19.8207
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CCK-81 CCLE -0.2247 3.8461 -0.7819 30.0978
SW48 CCLE 0.1105 18.7797 -7.4107 41.7672
C2BBe1 CCLE 1.2791 5.4909 0.1366 20.3135
T84 CCLE 1.9364 10.9247 -1.8802 26.6647
SK-CO-1 CCLE 2.2849 6.9319 0.4104 15.8156
NCI-H747 CCLE 2.3243 6.3777 0.7195 14.1064
COLO 678 CCLE 2.8555 7.6604 0.5483 13.5514
LS513 CCLE 2.9519 9.7629 -0.4216 18.0358
LS123 CCLE 3.1374 6.778 1.2243 9.2739
SW403 CCLE 3.2877 9.2042 0.1343 14.5533
SNU-C2B CCLE 3.328 8.2189 0.6586 11.8059
HCC-56 CCLE 3.4445 7.9437 0.8881 10.3362
COLO205 CCLE 3.4725 10.1276 -0.1781 15.6085
SNU-C2A CCLE 3.6067 7.222 1.3708 7.4202
SW1417 CCLE 3.6999 15.0119 -2.4331 23.8959
HT-29 CCLE 3.966 11.8916 -0.6686 16.6759
LS411N CCLE 4.1003 7.2931 1.6867 4.7974
COLO 320 CCLE 4.2444 10.9414 0.0126 12.9634
HCT 116 CCLE 4.887 6.2726 2.5473 0.2651
COLO201 CCLE 4.9648 6.3813 2.538 0.2568
HCT 15 CCLE 5.267 15.6582 -1.5536 17.4841
SW620 CCLE 5.537 18.4908 -2.7462 20.9901
RKO CCLE 6.626 15.5372 -0.5658 11.145
SW480 CCLE 8.5864 19.673 -1.2691 10.9721
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHH-5 CCLE -0.0234 2.1758 -0.1165 26.3729
JHH-4 CCLE 1.613 4.8046 0.7839 15.9628
SNU-449 CCLE 2.0095 4.6432 1.2558 12.2421
JHH-2 CCLE 2.1922 7.2999 0.1446 17.4193
HuH-1 CCLE 2.4554 6.404 0.8252 13.1813
Hep-G2/C3A CCLE 2.6957 5.4623 1.5068 8.88
SNU-475 CCLE 2.8001 4.8674 1.8949 6.5046
PLC/PRF/5 CCLE 3.014 6.2289 1.3972 8.6459
HLF CCLE 3.0669 6.6027 1.2541 9.2859
Hep 3B2.1-7 CCLE 3.1008 5.4618 1.8521 5.9738
SNU-182 CCLE 3.1416 6.5082 1.3625 8.5211
Hep-G2 CCLE 3.1787 5.3472 1.9718 5.1426
JHH-7 CCLE 3.3757 11.9951 -1.1885 20.2401
SK-HEP-1 CCLE 3.8221 6.7965 1.7355 5.0553
HLE CCLE 3.9106 8.6491 0.8938 9.2826
SNU-398 CCLE 4.0744 13.6717 -1.469 19.6849
SNU-387 CCLE 4.3754 7.9493 1.5563 4.9848
SNU-423 CCLE 5.4675 7.4129 2.3594 0.4547
JHH-6 CCLE 7.8205 22.4417 -3.0563 17.9613
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 94 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H3255 CCLE -3.2027 -0.6832 -3.2129 53.2286
PC-14 CCLE -1.8905 3.0888 -2.3617 43.1647
HCC827 CCLE -1.627 1.6972 -1.7628 40.2088
HCC2935 CCLE -1.2093 4.7627 -2.172 39.1814
HCC4006 CCLE -1.0681 1.2777 -1.1144 35.1311
CAL-12T CCLE -1.0456 5.6106 -2.3261 38.7837
NCI-H1666 CCLE -0.7595 10.1044 -4.0233 40.7271
NCI-H1650 CCLE 0.339 7.0413 -1.5142 30.6587
SK-MES-1 CCLE 0.4392 3.1619 0.1595 23.2543
NCI-H1793 CCLE 0.7369 7.0533 -1.1237 27.7693
NCI-H322 CCLE 0.743 2.2268 0.6969 19.5848
NCI-H1703 CCLE 0.9628 6.4756 -0.6316 24.9491
Calu-3 CCLE 1.0885 2.6336 1.0013 16.8027
LUDLU-1 CCLE 1.3011 7.1483 -0.6173 23.7437
NCI-H2170 CCLE 1.3312 4.7607 0.5154 18.2651
NCI-H2172 CCLE 1.3711 4.5881 0.6313 17.5499
NCI-H2085 CCLE 1.4392 5.4023 0.3376 18.7883
NCI-H358 CCLE 1.6223 4.7309 0.8263 15.7161
NCI-H1693 CCLE 1.6623 7.6834 -0.5324 22.2102
NCI-H1048 CCLE 1.7012 4.5046 1.0073 14.5311
SK-LU-1 CCLE 1.7513 4.5642 1.0319 14.2386
COR-L105 CCLE 1.8415 3.7575 1.4708 11.7094
NCI-H2030 CCLE 1.9814 6.518 0.3337 17.096
NCI-H727 CCLE 2.0284 4.562 1.3121 11.8892
EBC-1 CCLE 2.1331 4.2014 1.5817 10.1545
NCI-H1869 CCLE 2.2519 7.9032 -0.0999 18.439
Lu-99 CCLE 2.2919 4.9231 1.3993 10.6113
Sq-1 CCLE 2.3352 9.9972 -1.067 22.4909
SW1271 CCLE 2.3665 4.5993 1.6261 9.1865
DV-90 CCLE 2.3952 4.2287 1.8299 8.0248
T3M-10 CCLE 2.5628 7.5075 0.3723 15.2323
NCI-H2023 CCLE 2.6033 5.048 1.6292 8.4772
NCI-H1581 CCLE 2.788 4.0139 2.3071 4.3176
NCI-H2009 CCLE 2.8606 11.0727 -1.153 21.4078
LC-1/sq-SF CCLE 2.8741 5.7746 1.5064 8.4103
NCI-H1944 CCLE 2.875 15.4255 -3.3172 28.4125
NCI-H661 CCLE 2.9239 7.8868 0.4929 13.6596
NCI-H1341 CCLE 3.0344 7.942 0.5576 13.0463
HARA [Human squamous cell lung carcinoma] CCLE 3.092 17.7578 -4.3024 30.2252
NCI-H2444 CCLE 3.0969 6.0593 1.5503 7.6159
NCI-H647 CCLE 3.1304 5.8777 1.6683 6.897
IA-LM CCLE 3.1405 5.6881 1.7711 6.3171
NCI-H1915 CCLE 3.1572 10.8305 -0.785 19.1164
NCI-H650 CCLE 3.2265 7.2074 1.0819 9.821
SBC-5 CCLE 3.2355 7.6577 0.8644 10.9521
DMS 114 CCLE 3.2385 5.9403 1.7235 6.345
VMRC-LCD CCLE 3.2456 6.2419 1.5789 7.1086
COLO 699 CCLE 3.2543 6.1407 1.6363 6.7792
MOR/CPR CCLE 3.2669 5.9827 1.7248 6.2733
NCI-H2122 CCLE 3.2778 4.782 2.3285 3.0029
Hs 229.T CCLE 3.2802 6.0631 1.6952 6.4023
NCI-H1155 CCLE 3.3512 5.7533 1.9039 5.1207
NCI-H441 CCLE 3.3606 7.187 1.1989 8.8829
NCI-H1568 CCLE 3.3826 7.3508 1.1346 9.1751
NCI-H1355 CCLE 3.4366 9.0208 0.3452 13.1476
NCI-H2286 CCLE 3.4919 7.857 0.9683 9.8066
LOU-NH91 CCLE 3.5339 12.2552 -1.1906 19.8633
NCI-H1373 CCLE 3.5945 6.8324 1.5538 6.4725
NCI-H460 CCLE 3.6183 6.8045 1.5852 6.2557
NCI-H520 CCLE 3.6214 13.0376 -1.5108 20.8937
NCI-H1975 CCLE 3.7227 8.6961 0.7296 10.5352
NCI-H2087 CCLE 3.7349 7.3756 1.3903 7.047
NCI-H1651 CCLE 3.7705 6.9725 1.6135 5.7963
HCC15 CCLE 3.8002 7.0743 1.5851 5.8869
GLC-82 CCLE 3.8802 9.0956 0.6511 10.5945
NCI-H810 CCLE 3.9625 6.4994 1.9728 3.5773
NCI-H1792 CCLE 3.9915 9.941 0.3172 12.0312
HCC78 CCLE 4.1151 7.838 1.4354 6.0642
COLO 677 CCLE 4.1336 8.4927 1.1314 7.6014
NCI-H522 CCLE 4.1674 15.2758 -2.1942 22.0567
NCI-H211 CCLE 4.1784 6.584 2.0688 2.7578
Calu-6 CCLE 4.2301 7.614 1.62 4.9106
NCI-H1573 CCLE 4.2643 9.0929 0.9321 8.3704
NCI-H1648 CCLE 4.2822 7.5786 1.6708 4.5648
NCI-H1563 CCLE 4.3272 14.2656 -1.5685 19.4961
NCI-H2228 CCLE 4.3273 10.777 0.1545 12.1116
NCI-H226 CCLE 4.3659 6.6187 2.1623 2.062
NCI-H1299 CCLE 4.4584 9.5829 0.8304 8.5124
A-549 CCLE 4.5163 11.3697 0.0017 12.449
HCC44 CCLE 4.709 8.626 1.4517 4.9601
RERF-LC-A1 CCLE 4.7226 8.1326 1.6875 3.7943
COR-L23 CCLE 4.731 6.8704 2.2461 1.3058
NCI-H1694 CCLE 4.758 6.6818 2.3362 0.9475
SHP-77 CCLE 4.761 6.0172 2.5907 0.2206
RERF-LC-MS CCLE 4.7815 10.7032 0.513 9.477
NCI-H1092 CCLE 5.0551 6.8707 2.3936 0.5669
NCI-H1184 CCLE 5.2307 7.1469 2.3623 0.5589
Calu-1 CCLE 5.2329 10.4084 0.9501 6.5698
NCI-H23 CCLE 5.3721 7.3212 2.355 0.5081
NCI-H1339 CCLE 5.4016 12.145 0.2408 9.6554
SW1573 CCLE 5.7394 16.4664 -1.6093 16.7809
SW900 CCLE 6.0099 8.0672 2.3324 0.3167
KNS-62 CCLE 7.6546 26.6518 -5.207 23.6446
LCLC-103H CCLE 8.593 25.7667 -4.1271 19.701
⏷ Show the Full List of 94 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 15 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE-15 CCLE 0.1363 4.9089 -0.7947 28.6926
OE21 CCLE 0.1614 3.258 -0.1719 25.8707
KYSE-140 CCLE 0.7171 3.1747 0.4588 29.0133
KYSE-450 CCLE 1.1485 3.9222 0.6696 18.1466
KYSE-410 CCLE 1.6369 5.012 0.7141 16.239
KYSE-70 CCLE 1.8918 6.276 0.3666 17.2021
KYSE-520 CCLE 2.284 5.6858 1.022 12.6323
KYSE-180 CCLE 2.5001 6.4192 0.8578 12.8851
TE-9 CCLE 2.9875 5.7613 1.6089 7.5678
TE-1 CCLE 3.1229 6.7706 1.2161 9.353
KYSE-150 CCLE 3.251 4.9927 2.2043 3.726
OE33 CCLE 3.6215 8.7605 0.6199 11.3251
TE-5 CCLE 3.6708 8.8691 0.604 11.2955
KYSE-510 CCLE 4.2953 7.1842 1.8636 3.5822
KYSE-30 CCLE 5.1255 10.9606 0.6212 8.3338
⏷ Show the Full List of 15 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHOS-4 CCLE 0.8918 6.0522 -0.5083 24.6559
FU-OV-1 CCLE 1.429 10.26 -2.01 28.6198
OVCAR-3 CCLE 1.779 6.4119 0.1938 18.4146
A2780 CCLE 1.8433 6.3329 0.293 17.7212
TOV-21G CCLE 1.8983 6.0869 0.464 16.6879
EFO-21 CCLE 2.1944 6.3078 0.6346 14.9241
Kuramochi CCLE 2.2409 6.192 0.7344 14.2694
ONCO-DG-1 CCLE 2.2758 9.5837 -0.9133 22.0263
OC 315 CCLE 2.3385 4.6124 1.5928 9.4477
TYK-nu CCLE 2.3796 3.1932 2.2618 5.8739
TOV-112D CCLE 2.6622 6.8486 0.7874 12.8136
OC 316 CCLE 2.6831 5.2378 1.6071 8.3744
COV504 CCLE 2.8861 7.1092 0.8498 13.8335
MCAS CCLE 2.9056 5.6404 1.6003 7.8213
OC 314 CCLE 3.1948 6.8278 1.2459 9.0202
JHOS-2 CCLE 3.2953 7.363 1.0595 9.7777
SK-OV-3 CCLE 3.3279 16.8714 -3.6644 28.2108
OVMANA CCLE 3.4284 8.6161 0.5405 12.1772
OVSAHO CCLE 3.6392 6.6274 1.6875 5.6695
COV318 CCLE 3.9211 8.9665 0.7453 10.0254
OVCAR-4 CCLE 3.9911 6.8966 1.8029 4.3947
OV-90 CCLE 4.0055 7.9028 1.3276 6.8329
DOV13 CCLE 4.0206 6.5478 1.9874 3.4061
OVCAR-8 CCLE 4.0322 8.6766 0.9692 8.6416
ES-2 CCLE 4.8293 7.2198 2.1491 1.5947
⏷ Show the Full List of 25 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuP-T4 CCLE -0.5053 3.0144 -0.8294 31.4811
Capan-2 CCLE 1.1122 7.0643 -0.7604 24.9907
Panc 02.03 CCLE 1.1575 5.1479 0.1671 20.579
HPAC CCLE 1.5125 3.5571 1.1965 14.2467
HuP-T3 CCLE 2.276 7.3397 0.2007 16.8988
AsPC-1 CCLE 2.3523 6.0195 0.9215 12.9654
MIA PaCa-2 CCLE 2.526 7.1782 0.5039 14.66
HPAF-II CCLE 2.5632 7.5637 0.3446 15.3719
KCI-MOH1 CCLE 2.8746 6.1526 1.318 9.4249
Panc 10.05 CCLE 2.9271 8.363 0.2575 14.8456
PK-1 CCLE 3.0057 7.6748 0.6673 12.55
SUIT-2 CCLE 3.1712 7.5537 0.8642 11.1081
BxPC-3 CCLE 3.1725 12.2108 -1.4625 21.811
PL45 CCLE 3.1929 8.0842 0.6168 12.348
KP-3 CCLE 3.4351 6.1369 1.7777 5.6157
SU.86.86 CCLE 3.4725 6.3763 1.6876 6.0175
Panc 04.03 CCLE 3.5442 9.1859 0.348 12.8811
L3.3 CCLE 3.5694 8.8899 0.5151 11.9794
Panc 03.27 CCLE 3.6523 7.6813 1.1782 8.3434
SW1990 CCLE 3.7626 8.0035 1.1019 8.5097
Hs 766T CCLE 3.8555 12.013 -0.8149 17.557
KP-1N CCLE 4.0591 9.3889 0.6395 10.274
PK-45H CCLE 4.1526 11.3171 -0.2414 14.3484
PSN1 CCLE 4.1684 7.3394 1.7097 4.5612
KP-4 CCLE 4.2435 11.6731 -0.3488 14.6416
QGP-1 CCLE 4.6854 8.2287 1.621 4.1697
PK-59 CCLE 4.7318 11.6595 0.0149 11.955
PaTu 8902 CCLE 4.7371 12.2212 -0.2552 13.188
KP-1NL CCLE 6.7711 18.9077 -2.0728 16.5741
⏷ Show the Full List of 29 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H28 CCLE 0.8658 6.5373 -0.7566 25.8233
IST-Mes1 CCLE 1.3399 5.3969 0.2404 19.6003
IST-Mes2 CCLE 2.8242 4.5111 2.0934 5.3678
MSTO-211H CCLE 3.2378 8.0413 0.6747 11.9388
MPP 89 CCLE 3.3288 5.8046 1.8614 5.3983
NCI-H2052 CCLE 3.9269 9.055 0.706 10.2142
NCI-H2452 CCLE 3.9968 7.9714 1.2881 7.0558
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DU145 CCLE 1.6004 5.6714 0.3729 18.0855
PC-3 CCLE 2.4288 6.7746 0.6178 14.3405
22Rv1 CCLE 5.0703 7.8295 2.0143 1.8967
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 CCLE 2.8407 7.3515 0.6901 12.8532
Cancer Drug Sensitivity Data Curated from 41 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HMCB CCLE 1.5417 5.8089 0.2508 18.8843
CHL-1 CCLE 1.9615 5.4561 0.8268 14.6252
Mel Ho CCLE 1.9796 2.9114 1.9093 9.078
K029AX CCLE 2.0753 3.034 1.9814 8.3666
WM983B CCLE 2.0863 4.7967 1.2602 11.9755
Hs 938.T CCLE 2.15 3.0111 2.0693 7.6645
SK-MEL-31 CCLE 2.2174 3.7118 1.8839 8.3273
G-361 CCLE 2.2655 3.0393 2.1874 6.6618
Hs 936.T CCLE 2.2842 2.8552 2.2531 6.285
Hs 852.T CCLE 2.3697 5.338 1.2716 11.0581
SK-MEL-24 CCLE 2.5463 4.2265 1.9771 6.7854
Malme-3M CCLE 2.6812 7.4257 0.5162 14.1761
WM266-4 CCLE 2.8598 6.6386 1.0626 10.8339
RPMI-7951 CCLE 2.8782 4.4128 2.1897 4.7033
UACC-257 CCLE 2.9291 4.2019 2.339 3.7622
Hs 895.T CCLE 3.2437 4.8156 2.2864 3.301
MeWo CCLE 3.3777 4.7678 2.4077 2.3827
SK-MEL-5 CCLE 3.383 5.0508 2.2736 3.0792
WM793 CCLE 3.4393 8.8959 0.4097 12.8164
IGR-39 CCLE 3.4411 18.9568 -4.6139 30.1026
IGR-37 CCLE 3.6464 6.1085 1.9459 4.2896
WT2-iPS CCLE 3.6616 9.4915 0.2878 12.9112
A-375 CCLE 3.9094 10.2912 0.0818 13.3606
LOX-IMVI CCLE 4.0951 8.8975 0.9066 8.8362
RVH-421 CCLE 4.1893 9.7591 0.5531 10.4396
Hs 294T CCLE 4.212 9.3379 0.7756 9.2705
Hs 944.T CCLE 4.2517 7.7313 1.5786 5.0836
SK-MEL-2 CCLE 4.2527 5.3232 2.644 0.3082
SK-MEL-30 CCLE 4.3183 5.9562 2.4223 1.0084
MDA-MB-435S CCLE 4.4227 13.2088 -0.9727 16.9515
Hs 695T CCLE 4.5637 9.0327 1.1661 7.7033
COLO 741 CCLE 4.6517 8.2721 1.5803 4.4193
HT-144 CCLE 4.6811 8.218 1.6233 4.165
UACC-62 CCLE 4.7354 9.9436 0.8462 7.9213
SF8657 CCLE 4.8218 7.7898 1.8989 2.6765
WM1799 CCLE 5.0186 16.5258 -2.1632 20.1432
COLO 679 CCLE 5.0494 6.6985 2.4557 0.4071
WM88 CCLE 5.1325 7.3714 2.2327 1.0178
A2058 CCLE 5.5733 18.0585 -2.5072 20.1741
IPC-298 CCLE 7.9931 20.1226 -1.8439 13.8401
WM115 CCLE 8.6488 21.6061 -2.1226 13.8193
⏷ Show the Full List of 41 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 13 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE 617.T CCLE 0.0528 2.1106 -0.0244 25.649
A-204 CCLE 0.4483 5.0355 -0.5187 26.3145
G-401 CCLE 2.3836 4.4505 1.7136 8.6729
SK-LMS-1 CCLE 2.5286 6.3702 0.9075 12.5433
RD CCLE 2.5871 4.3882 1.9376 6.8735
HT-1080 CCLE 2.6019 4.6032 1.8466 7.3164
G-402 CCLE 2.7574 5.4838 1.5505 8.4782
KYM-1 CCLE 3.1212 4.7668 2.2155 3.9586
GCT CCLE 3.1669 4.506 2.3812 2.9601
Rh30 CCLE 3.2294 11.5475 -1.0841 20.1833
Hs 729.T CCLE 3.6562 5.5461 2.2235 2.8273
RKN CCLE 5.1358 16.2859 -1.9579 19.2027
MES-SA CCLE 6.013 18.4218 -2.3669 18.8955
⏷ Show the Full List of 13 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NUGC-4 CCLE -0.5218 4.0595 -1.1772 32.92
SNU-16 CCLE 1.0141 2.6672 0.9137 17.501
IM95 CCLE 1.1545 4.6414 0.3839 19.5282
NUGC-3 CCLE 1.1595 4.2466 0.5531 18.6781
Fu97 CCLE 1.2136 3.6681 0.8345 17.1061
AZ-521 CCLE 1.2983 3.7843 0.8823 16.5627
KE-39 CCLE 1.3681 6.9179 -0.4428 22.7479
GCIY CCLE 1.4007 5.6498 0.1853 19.669
RERF-GC-1B CCLE 1.4777 6.5186 -0.1468 21.0219
HGC-27 CCLE 2.3281 5.9066 0.9548 12.859
NCI-N87 CCLE 3.1691 6.2796 1.4989 7.7202
Hs 746.T CCLE 3.3592 5.007 2.2778 3.1049
SH-10-TC CCLE 3.8495 7.1145 1.6005 5.7096
MKN45 CCLE 3.9139 5.0037 2.6184 0.6263
BGC-823 CCLE 4.2878 8.6627 1.1568 7.1759
OCUM-1 CCLE 4.4046 7.9012 1.5978 4.7277
MKN74 CCLE 4.9094 12.8809 -0.4537 13.7296
SNU-1 CCLE 5.0287 9.9651 1.0281 6.5223
MKN7 CCLE 5.1884 8.3167 1.8678 2.3806
SNG-M CCLE 6.0382 20.9184 -3.5705 22.4189
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW579 CCLE 1.8957 6.5605 0.2326 17.8629
TT2609-C02 CCLE 3.0307 5.9517 1.5496 7.7813
8305C CCLE 3.4392 6.5945 1.5543 6.8037
8505C CCLE 3.8381 13.6036 -1.6206 20.7932
B-CPAP CCLE 3.8997 8.1992 1.1068 8.1976
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CAL-27 CCLE -1.3095 3.6219 -1.8865 38.927
SCC-9 CCLE -0.1706 5.5682 -1.3884 32.2053
SCC-25 CCLE 0.5741 5.1579 -0.439 25.4928
Detroit 562 CCLE 1.6622 5.7118 0.4146 17.6778
FaDu CCLE 1.7023 5.7735 0.4247 17.499
Hs 840.T CCLE 2.0724 7.3051 0.0328 18.3194
HSC-2 CCLE 3.2314 6.256 1.5606 7.2406
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 14 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SCaBER CCLE -0.3162 3.9551 -0.9185 31.0373
RT-4 CCLE 0.9494 6.7861 -0.7893 25.6695
JMSU-1 CCLE 1.1611 4.0892 0.6179 18.3545
HT-1376 CCLE 1.3326 5.4373 0.2147 19.7516
RT-112 CCLE 1.6599 7.2584 -0.3281 21.2899
639V CCLE 2.2071 9.0609 -0.7142 21.3758
5637 CCLE 2.3472 4.2086 1.7922 8.3732
HT-1197 CCLE 2.829 10.3881 -0.8375 20.1888
UM-UC-3 CCLE 2.9002 5.5462 1.6428 7.6053
J82 CCLE 3.2293 6.1019 1.6358 6.8399
KMBC-2 CCLE 3.2454 6.2977 1.551 7.2597
SW780 CCLE 3.2892 7.493 0.9898 10.1619
T24 CCLE 3.6091 15.3021 -2.6511 24.7824
TCCSUP CCLE 4.0394 5.9334 2.2822 1.9392
⏷ Show the Full List of 14 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Vandetanib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [12]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Vandetanib and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [13]
Coadministration of a Drug Treating the Disease Different from Vandetanib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Vandetanib and Ivosidenib. Acute myeloid leukaemia [2A60] [13]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Vandetanib and Midostaurin. Acute myeloid leukaemia [2A60] [13]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Vandetanib and Arn-509. Acute myeloid leukaemia [2A60] [13]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Vandetanib and Oliceridine. Acute pain [MG31] [13]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Vandetanib and Ivabradine. Angina pectoris [BA40] [14]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Vandetanib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [13]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Vandetanib and Levalbuterol. Asthma [CA23] [15]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Vandetanib caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [16]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Vandetanib and Eribulin. Breast cancer [2C60-2C6Y] [13]
Talazoparib DM1KS78 Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [17]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Vandetanib and Bosutinib. Breast cancer [2C60-2C6Y] [13]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Vandetanib and Olodaterol. Chronic obstructive pulmonary disease [CA22] [18]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Vandetanib and Vilanterol. Chronic obstructive pulmonary disease [CA22] [15]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Vandetanib and Osilodrostat. Cushing syndrome [5A70] [13]
Lumacaftor DMCLWDJ Moderate Increased metabolism of Vandetanib caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [19]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Vandetanib and Deutetrabenazine. Dystonic disorder [8A02] [13]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Vandetanib and Ingrezza. Dystonic disorder [8A02] [13]
Cenobamate DM8KLU9 Moderate Increased metabolism of Vandetanib caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Dexlansoprazole DM1DBV5 Minor Decreased absorption of Vandetanib due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [12]
Ripretinib DM958QB Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [12]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [21]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Vandetanib and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [13]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Vandetanib and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [13]
Aliskiren DM1BV7W Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [13]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Vandetanib and Polyethylene glycol. Irritable bowel syndrome [DD91] [22]
Naloxegol DML0B41 Minor Decreased clearance of Vandetanib due to the transporter inhibition by Naloxegol. Large intestine motility disorder [DB32] [23]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Vandetanib and Crizotinib. Lung cancer [2C25] [13]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Vandetanib and Osimertinib. Lung cancer [2C25] [13]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Vandetanib and Selpercatinib. Lung cancer [2C25] [13]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Vandetanib and Lumefantrine. Malaria [1F40-1F45] [12]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Vandetanib and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [13]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Vandetanib and Idelalisib. Mature B-cell leukaemia [2A82] [24]
GDC-0199 DMH0QKA Major Decreased clearance of Vandetanib due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [12]
IPI-145 DMWA24P Moderate Increased metabolism of Vandetanib caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [25]
Arry-162 DM1P6FR Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Arry-162. Melanoma [2C30] [12]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Vandetanib and LGX818. Melanoma [2C30] [13]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Vandetanib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [14]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Vandetanib and Panobinostat. Multiple myeloma [2A83] [13]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Vandetanib and Siponimod. Multiple sclerosis [8A40] [12]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Vandetanib and Fingolimod. Multiple sclerosis [8A40] [13]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Vandetanib and Ozanimod. Multiple sclerosis [8A40] [13]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Vandetanib and Romidepsin. Mycosis fungoides [2B01] [13]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Vandetanib and Rucaparib. Ovarian cancer [2C73] [13]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Vandetanib and Triclabendazole. Parasitic worm infestation [1F90] [13]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Vandetanib and Pimavanserin. Parkinsonism [8A00] [13]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Vandetanib and Macimorelin. Pituitary gland disorder [5A60-5A61] [26]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Vandetanib and Lefamulin. Pneumonia [CA40] [13]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Vandetanib and Degarelix. Prostate cancer [2C82] [13]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Vandetanib and ABIRATERONE. Prostate cancer [2C82] [13]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Vandetanib and Enzalutamide. Prostate cancer [2C82] [13]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Vandetanib and Relugolix. Prostate cancer [2C82] [13]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Vandetanib and Amisulpride. Schizophrenia [6A20] [13]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Vandetanib and Asenapine. Schizophrenia [6A20] [13]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Vandetanib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [14]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Vandetanib and Pitolisant. Somnolence [MG42] [13]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Vandetanib and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [13]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Vandetanib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [27]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Vandetanib due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [12]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Vandetanib and Lenvatinib. Thyroid cancer [2D10] [13]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Vandetanib and Cabozantinib. Thyroid cancer [2D10] [13]
⏷ Show the Full List of 60 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Brushite E00392 104805 Diluent
Crospovidone E00626 Not Available Disintegrant
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 300 E00651 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Vandetanib 100 mg tablet 100 mg Oral Tablet Oral
Vandetanib 300 mg tablet 300 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5717).
2 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
5 Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol. 2010 Jan;65(2):335-46.
6 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
7 FDA label of Vandetanib. The 2020 official website of the U.S. Food and Drug Administration.
8 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
9 ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Int J Cancer. 2006 Jan 15;118(2):483-9. doi: 10.1002/ijc.21340.
10 Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. Cancer Sci. 2004 Dec;95(12):984-9. doi: 10.1111/j.1349-7006.2004.tb03187.x.
11 Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma. Br J Cancer. 2013 Jul 9;109(1):164-71. doi: 10.1038/bjc.2013.306. Epub 2013 Jun 25.
12 Cerner Multum, Inc. "Australian Product Information.".
13 Canadian Pharmacists Association.
14 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
15 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
16 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
17 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
18 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
19 Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
20 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
21 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
22 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
23 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
24 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
25 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
26 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
27 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.